CDEK
← All organizations

Sankyo

For profitContributed to NME

Also known as: AM REGENT | SANKYO | Sankyo Shanghai Pharmaceuticals | Shanghai Sankyo Pharmaceuticals Co., Ltd.

Phase 1Phase 2Phase 3Phase 4

Highest phase reached

Phase 4

First clinical trial

Nov 1, 2001

First marketed drug

Apr 26, 1972

First NDA

Jan 29, 1997

Last known activity

Aug 1, 2006

Acquired by Daiichi Sankyo on Jan 1, 2005

Timeline

1890s

  1. Jan 1, 1899

    Sankyo— Founded

1990s

  1. Jan 1, 1991

    Lutipold— Acquired

  2. Aug 7, 1992

    cefpodoxime— NDA Secondary Org

  3. Jan 29, 1997

    troglitazone— NDA Organization

2000s

  1. Jan 1, 2005

    Daiichi Sankyo— Acquired By

2010s

  1. Aug 23, 2013

    dactinomycin— Marketing Organization

Drugs by trial phase (7 distinct, 11 trials)

Phase 4 (2 own, 0 via acquisition)

Phase 3 (4 own, 0 via acquisition)

Phase 2 (1 own, 0 via acquisition)

Indications

Approved for

Studied for

Marketed drugs (79)

Subsidiaries (1 direct, 2 total across the full acquisition tree)

Recent trials (13)

Details

Founded
Tokyo, JP Jan 1, 1899
First NDA
Jan 29, 1997
Last known activity
Aug 1, 2006

Designations held

  • Priority review